BTG Pactual will likely buy most of the shares on offer, but other investors are concerned by BR Pharma’s level of debt, sources say
This is a limited version of LatinFinance UNLOCK FULL ACCESS
BTG Pactual will likely buy most of the shares on offer, but other investors are concerned by BR Pharma’s level of debt, sources say